BNTX vs. PFE: A Head-to-Head Stock Comparison

Updated on October 3, 2025

Here’s a clear look at BNTX and PFE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

BNTX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, PFE is a standard domestic listing.

Symbol	BNTX	PFE
Company Name	BioNTech SE	Pfizer Inc.
Country	Germany	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Pharmaceuticals
Market Capitalization	24.57 billion USD	154.70 billion USD
Exchange	NasdaqGS	NYSE
Listing Date	October 10, 2019	June 1, 1972
Security Type	ADR	Common Stock

Historical Performance

This chart compares the performance of BNTX and PFE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BNTX vs. PFE: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	BNTX	PFE
5-Day Price Return	-1.13%	5.77%
13-Week Price Return	-7.37%	5.12%
26-Week Price Return	2.84%	1.07%
52-Week Price Return	-16.58%	-12.41%
Month-to-Date Return	-1.38%	2.91%
Year-to-Date Return	-13.45%	-3.96%
10-Day Avg. Volume	0.93M	60.80M
3-Month Avg. Volume	0.93M	43.07M
3-Month Volatility	36.97%	27.90%
Beta	1.59	0.51

Profitability

Return on Equity (TTM)

BNTX

-1.82%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

BNTX has a negative Return on Equity of -1.82%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

PFE

11.96%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

PFE’s Return on Equity of 11.96% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

BNTX vs. PFE: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

BNTX

-24.18%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

BNTX has a negative Net Profit Margin of -24.18%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

PFE

16.85%

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

PFE’s Net Profit Margin of 16.85% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

BNTX vs. PFE: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

BNTX

-47.77%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

BNTX has a negative Operating Profit Margin of -47.77%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

PFE

18.62%

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

PFE’s Operating Profit Margin of 18.62% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

BNTX vs. PFE: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	BNTX	PFE
Return on Equity (TTM)	-1.82%	11.96%
Return on Assets (TTM)	-1.57%	5.08%
Net Profit Margin (TTM)	-24.18%	16.85%
Operating Profit Margin (TTM)	-47.77%	18.62%
Gross Profit Margin (TTM)	84.90%	73.96%

Financial Strength

Current Ratio (MRQ)

BNTX

8.61

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

BNTX’s Current Ratio of 8.61 is in the upper quartile for the Biotechnology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

PFE

1.16

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

PFE’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

BNTX vs. PFE: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BNTX

0.01

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

PFE

0.70

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

PFE’s Debt-to-Equity Ratio of 0.70 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

BNTX vs. PFE: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

BNTX

-1.43

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

PFE

7.89

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

PFE’s Interest Coverage Ratio of 7.89 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

BNTX vs. PFE: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	BNTX	PFE
Current Ratio (MRQ)	8.61	1.16
Quick Ratio (MRQ)	8.48	0.85
Debt-to-Equity Ratio (MRQ)	0.01	0.70
Interest Coverage Ratio (TTM)	-1.43	7.89

Growth

Revenue Growth

BNTX vs. PFE: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BNTX vs. PFE: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BNTX

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

PFE

6.21%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

With a Dividend Yield of 6.21%, PFE offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

BNTX vs. PFE: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

BNTX

17.60%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

PFE

89.67%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

PFE’s Dividend Payout Ratio of 89.67% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

BNTX vs. PFE: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	BNTX	PFE
Dividend Yield (TTM)	0.00%	6.21%
Dividend Payout Ratio (TTM)	17.60%	89.67%

Valuation

Price-to-Earnings Ratio (TTM)

BNTX

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for BNTX is currently unavailable.

PFE

14.45

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

In the lower quartile for the Pharmaceuticals industry, PFE’s P/E Ratio of 14.45 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

BNTX vs. PFE: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

BNTX

7.36

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

BNTX’s P/S Ratio of 7.36 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

PFE

2.43

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

PFE’s P/S Ratio of 2.43 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

BNTX vs. PFE: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

BNTX

1.18

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

BNTX’s P/B Ratio of 1.18 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

PFE

1.55

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

PFE’s P/B Ratio of 1.55 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

BNTX vs. PFE: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	BNTX	PFE
Price-to-Earnings Ratio (TTM)	--	14.45
Price-to-Sales Ratio (TTM)	7.36	2.43
Price-to-Book Ratio (MRQ)	1.18	1.55
Price-to-Free Cash Flow Ratio (TTM)	172.95	11.39